Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8631677 | 0.77 | POLB (0.39) | TDP1POLBALDH1A1 | |
| SCHEMBL15156765 | 0.75 | KDM4E (0.31) | ALDH1A1KDM4EMAPT | |
| SCHEMBL15157202 | 0.75 | KDM4E (0.31) | ALDH1A1KDM4EMAPT | |
| SCHEMBL2581832 | 0.74 | SMN1; SMN2 (0.38) | TDP1SMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL14021448 | 0.74 | SMN1; SMN2 (0.38) | TDP1SMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL5708919 | 0.74 | SMN1; SMN2 (0.38) | TDP1SMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL16169953 | 0.74 | POLB (0.41) | TDP1POLBSMN1; SMN2 | |
| SCHEMBL7887353 | 0.73 | — | — | |
| SCHEMBL5708888 | 0.70 | SMN1; SMN2 (0.39) | TDP1POLBSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL18101503 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877349-B2 | Organometallic complex and organic electroluminescence device using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2014-11-04 | — | — | US | claimed |
| US-8039123-B2 | Phosphorescent heteronuclear copper(I)-iridium(III) complex and organic electroluminescence device using the same | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2011-10-18 | — | — | US | claimed |
| EP-1874132-A1 | HOT FLAVOUR AND SKIN SENSATION COMPOSITION | FIRMENICH SA (CH) | 2008-01-09 | — | — | EP | claimed |
| US-20070267959-A1 | Phosphorescent heteronuclear copper(I)-iridium(III) complex and organic electroluminescence device using the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2007-11-22 | — | — | US | claimed |
| US-7294415-B2 | Organometallic complex and organic electroluminescent device employing the same | SAMSUNG SDI CO., LTD. (KR) | 2007-11-13 | — | — | US | claimed |
| US-20070178332-A1 | highly efficient phosphorescent organometallic complex and an organic electroluminescent (EL) device using the same. The organometallic complex can be used in the formation of an organic layer of the organic EL device, and can emit red light from phosphorescent material | SAMSUNG DISPLAY CO., LTD. (KR) | 2007-08-02 | — | — | US | claimed |
| WO-2006109241-A1 | HOT FLAVOUR AND SKIN SENSATION COMPOSITION | FIRMENICH SA (CH) | 2006-10-19 | — | — | WO | claimed |
| US-20040265633-A1 | Organometallic complex and organic electroluminescent device employing the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2004-12-30 | — | — | US | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| EP-3643735-B1 | PHOTOCHROMIC POLYROTAXANE COMPOUND, AND CURABLE COMPOSITION CONTAINING SAID PHOTOCHROMIC POLYROTAXANE COMPOUND | TOKUYAMA CORP (JP) | 2024-07-31 | — | — | EP | disclosed |
| EP-3498742-B1 | PHOTOCHROMIC CURABLE COMPOSITION, USE THEREOF, AND POLYROTAXANE MONOMERS | TOKUYAMA CORP (JP) | 2024-06-12 | — | — | EP | disclosed |
| US-20240101751-A1 | HOLLOW MICROBALLOON | TOKUYAMA CORPORATION (JP) | 2024-03-28 | — | — | US | disclosed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | disclosed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0207773-A2 | 7-[(Substituted)amino]-8-[(substituted)carbonyl)-methylamino]-1-oxaspiro[4.5]decanes as analgesic agents | WARNER-LAMBERT COMPANY (US) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070267959-A1 | Phosphorescent heteronuclear copper(I)-iridium(III) complex and organic electroluminescence device using the same | ORC3, AP3M1, PUF60 | TDP1 2901/4885POLB 834/4885SMN1; SMN2 2630/4885 |
| US-20040265633-A1 | Organometallic complex and organic electroluminescent device employing the same | TYR, CYBA, LAGE3 | TDP1 4281/4885POLB 2744/4885SMN1; SMN2 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.